| Study Period | 2019 - 2030 |
| 2024 Market Size | USD 4,018.0 Million |
| 2025 Market Size | USD 4,327.4 Million |
| 2030 Forecast | USD 6,447.1 Million |
| Growth Rate (CAGR) | 8.3% |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Nature of the Market | Fragmented |
| Largest End User Category | Hospitals and Clinics |
|
Explore the market potential with our data-driven report
The embolotherapy market will generate an estimated revenue of USD 4,018.0 million in 2024, which is projected to reach USD 6,447.1 million in 2030 at a CAGR of 8.3% during the forecast period (2025–2030).
The growing patient pool, escalating prevalence of chronic and lifestyle-associated diseases, increasing healthcare expenditure, and improving healthcare infrastructure are some of the chief factors driving the growth of the market. This is also credited to the advancements in medical technology and the favorable government initiatives and policies for public health improvement.
The substantial investments in healthcare infrastructure, availability of advanced embolic agents and devices, and rapid adoption of minimally invasive surgical procedures further boost the growth of the market. Surgeries that have fewer complications and faster recoveries are increasingly being sought after by patients, which is driving the demand for embolotherapy.
The increasing focus on research and development worldwide, along with the increasing public awareness of cancer treatment, drives the adoption of high-end embolotherapy treatments.
The embolotherapy market is witnessing growth on account of an increase in the number of patients seeking embolization treatments for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), varicose veins, and aneurysms. According to the Centers for Disease Control and Prevention (CDC), almost 10,000 people in the U.S. die each year from aortic aneurysms, which shows the unmet need for such procedures.
The market is also bolstered by the rise in the demand for minimally invasive surgical technologies. These procedures require much less time to recover from in contrast to traditional surgeries, while reducing the chances of complications and infections. Since they are precise and image-guided, they also cause less damage to surrounding tissues. Further, the advancements in imaging, embolic agents, and catheter technology make these therapies increasingly effective.
To address the rising cases of chronic diseases, governments across the globe are significantly investing to improve the healthcare infrastructure and advance medical facilities. As per the World Health Organization, global expenditure on health rose to a staggering USD 9.8 trillion in 2021, accounting for 10.35% of the worldwide GDP. This increase supports the establishment of new hospitals and the procurement of high-tech medical equipment.
The U.S., Japan, and Germany are seeking to modernize their healthcare infrastructure by purchasing high-tech equipment and training professionals to employ minimally invasive surgical technologies. Moreover, in emerging economies, such as Brazil, China, and India, well-equipped hospitals and specialized interventional radiology units are being constructed.
Notably, the expansion of services to places that lack access through mobile health units, satellite healthcare centers, and telemedicine helps address chronic diseases and boosts the demand for medical products.
Prolonged exposure to four modifiable lifestyle behaviors, namely smoking, unhealthy diet, alcohol consumption, and physical inactivity, often results in chronic diseases, including stroke, diabetes, obesity, metabolic syndrome, chronic obstructive pulmonary disease, and various types of cancer. Chronic diseases are a major healthcare burden affecting high-income as well as low- and middle-income countries (LMICs). Cancer, hepatitis, and central nervous system disorders are some of the chronic diseases that require advanced treatment.
The rise in the acceptance of image-guided procedures provides a great opportunity to the global embolotherapy market. They employ MRI, fluoroscopy, and CT, which allow surgeons to achieve high accuracy in embolization with minimal tissue damage during navigation. Essentially, the market is growing due to the rising consciousness of the benefits of minimally invasive, image-guided treatments.
Furthermore, the transition toward value-based care, where value is placed over cost and on improved outcomes at a reduced cost, propels the demand for embolic agents and support devices.
Embolic agents dominate the embolotherapy market in 2024 with revenue of USD 3,535.3 million. The increasing use of embolic agents in various interventional radiological procedures is the primary reason for this category's dominance on the market.
Furthermore, due to the advancements in such agents, such drug-eluting microspheres, as calibrated microspheres for bland embolization, and radioactive yttrium-90 microspheres, for primary or secondary diseases of the liver, the category is expected to advance at the highest rate over the forecast period.
The escalating rates of HCC directly drive the demand for microspheres, as they are widely used for the treatment of HCC. As per the American Cancer Society, more than 850,000 diagnoses of liver cancer are registered around the world every year.
The ongoing research on developing biodegradable and multifunctional microspheres is another key driver for this category. These microspheres can offer an effective treatment for HCC by conjugating therapeutic radionuclides with chemotherapeutic agents.
The products evaluated in this report are:
Transcatheter arterial embolization (TAE) leads the embolotherapy market, and it is expected to be the fastest-growing category, at a CAGR of 8.9%, during the forecast period. This is attributed to the proliferating demand for minimally invasive procedures and the rapidly growing geriatric population. TAE is effective and well-tolerated in patients with ruptured HCCs, and it is preferred over transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)/selective internal radiation therapy (SIRT).
The procedures analyzed here are:
Cancer is the largest category in the embolotherapy market, and it is projected to reach a value of USD 2,736.4 million in 2030. Embolization is majorly used for the treatment of cancer, including kidney and liver cancers. It has the advantage directly detecting and targeting tumors, while minimizing the impact on the tissues around the embolization site. Superior imaging and more-potent embolic agents make embolization a far more potent oncological procedure.
The indications evaluated here are:
The hospitals and clinics category will generate the highest revenue, of USD 3,182.1 million, in 2024. The major end users of embolotherapy devices and embolic agents are large hospitals, small clinics, and critical care units. The increasing adoption of minimally invasive surgical procedures, including vascular, neurological, and urological interventions, is driving the volume of embolotherapy procedures at these places.
Well-equipped hospitals with infrastructure that supports comprehensive patient care, such as departments of interventional radiology, are preferred for embolization procedures. Hospitals also have more patients in comparison to ambulatory surgical centers and thus, create a higher demand for embolotherapy devices and embolic agents.
Additionally, the increasing buying power of major healthcare providers and availability of reimbursement for embolotherapy procedures in the U.S. and other major European markets drive the growth of this category.
The end users evaluated here are:
Drive strategic growth with comprehensive market analysis
North America is expected to generate the highest market revenue, of USD 2,449.7 million, in 2030. The increasing prevalence of indications that require embolization procedures, established healthcare ecosystem, and development of advanced embolic agents by the players operating in the region propel the North American market. The American Cancer Society estimated 1.9 million cancer cases and 609,360 related deaths in the U.S. in 2022.
Further, the rising geriatric population is a key driver for the market in the region as these people are highly vulnerable to cancer and other severe diseases. According to the Population Reference Bureau, the number of people in the age group of 65 and above in the U.S. is predicted to increase by a massive 47%, to 82 million by 2050 from 58 million in 2022.
APAC is expected to emerge as the fastest-growing region for embolotherapy, at a CAGR of 9.7%, during the forecast period. China and India are experiencing rapid economic growth, leading to the increasing consumer spending and investment in healthcare. The region also has a rapidly growing population, which creates a substantial market for embolotherapy.
The increasing foreign direct investment (FDI) into the regional healthcare industry also encourages businesses in the market to innovate. As per the IBEF, the country’s medical and surgical appliance sector received FDI worth USD 3.28 billion from April 2000 to March 2024. Moreover, FDI in hospitals and diagnostic centers stood at USD 10.26 billion for the same period.
Another key driver for the market in the region is its growing medical tourism industry. Compared to the U.S. and Western European countries, India, Singapore, Malaysia, Vietnam, Thailand, and other APAC nations offer less-costly treatments for even complex conditions, including cancers.
The regions and countries we have analyzed here are:
The embolotherapy market is fragmented in nature because there are numerous multinationals and smaller, specialized enterprises. They all specialize in different products for vascular embolization, tumor embolization, and uterine fibroid embolization. Embolotherapy is applied in numerous fields, such as oncology, interventional radiology, and vascular surgery, which leads to a diversity of products and services, thus widening the scope for new players. Further, different countries have different market dynamics, regulations, and customer preferences, which further contributes to a fragmented landscape.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages